Clinical Trial Update: Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sildenafil therapy for sickle cell disease and pulmonary hypertension has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Sickle Cell Disease

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Sickle Cell Disease, Pulmonary Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2011-06-06